Fertility and Sterility
Volume 90, Issue 4 , Pages 965-971 , October 2008

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

  • Kavita Nanda, M.D., M.H.S.

      Affiliations

    • Family Health International, Research Triangle Park, North Carolina
    • Corresponding Author InformationReprint requests: Kavita Nanda, M.D., M.H.S., Family Health International, P.O. Box 13950, Research Triangle Park, NC 27709 (FAX: 919-544-7261).
    • ,
  • Eliana Amaral, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, Campinas, Brazil
    • ,
  • Melissa Hays, M.P.H.

      Affiliations

    • Family Health International, Research Triangle Park, North Carolina
    • ,
  • Marco A.M. Viscola, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, Campinas, Brazil
    • ,
  • Neha Mehta, M.P.H.

      Affiliations

    • Family Health International, Research Triangle Park, North Carolina
    • ,
  • Luis Bahamondes, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas, Campinas, Brazil

Received 26 February 2007 ,Revised 16 July 2007 ,Accepted 18 July 2007.

References 

  1. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res. 2000;6:3297–3303
  2. Brasil Ministério da Saúde . Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV. Brasília: Brasil Ministério da Saúde. 2006;
  3. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [monograph]. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 30, 2006.
  4. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach [monograph]. April 2002. Available at: http://www.who.int/hiv/topics/arv/scaling_exe_summary.pdf. Accessed November 30, 2006.
  5. Gilead Sciences. Tenofovir prescribing information. Available at: http://www.gilead.com/pdf/viread_pi.pdf. Accessed November 30, 2006.
  6. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111–116
  7. Mildvan D, Yarrish R, Marshak A, Hutman HW, McDonough M, Lamson M, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002;29:471–477
  8. Chu JH, Gange SJ, Anastos K, Minkoff H, Cejtin H, Bacon M, et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol. 2005;161:881–890
  9. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr. 2006;42:29–35
  10. Halpenny O, Bye A, Cranny A, Feely J, Daly PA. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate. Med Oncol Tumor Pharmacother. 1990;7:241–247
  11. Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol. 1990;27:101–105
  12. De Souza A, Brechin S, Penney G. The members' enquiry service: frequently asked questions. J Fam Plann Reprod Health Care. 2004;30:190–191
  13. Scottish Intercollegiate Guidelines Network. Guideline no. 70: diagnosis and management of epilepsy in adults [monograph]. Available at: http://www.sign.ac.uk/guidelines/fulltext/70/index.html. Accessed November 30, 2006.
  14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations [monograph]. Available at: http://www.fda.gov/cder/guidance/5356fnl.pdf. Accessed November 30, 2006.
  15. da Silveira Rossi A, Fonsechi-Carvasan GA, Makuch MY, Amaral E, Bahamondes L. Factors associated with reproductive options in HIV-infected women. Contraception. 2005;71:45–50
  16. Reynolds HW, Janowitz B, Homan R, Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis. 2006;33:350–356
  17. Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007;81:222–227
  18. Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab. 1977;44:32–38
  19. Shrimanker K, Saxena BN, Fotherby K. A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem. 1978;9:359–363
  20. Karkkainen J, Vesterinen E, Stenman UH, Adlercreutz H, Nieminen U, Widholm O. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer. Eur J Cancer. 1990;26:975–977
  21. Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust. 1981;1(Suppl 1):3–19
  22. Pharmacia Limited. Depo-Provera® 150 mg/ml summary of product characteristics. Available at: http://emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?DocumentID=11121. Accessed November 30, 2006.
  23. Gupta C, Osterman J, Santen R, Bardin CW. In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women. J Clin Endocrinol Metab. 1979;48:816–820

 Support for this work was provided by funds from the United States Agency for International Development (USAID) (cooperative agreements nos. AID/CCP-3079-A-00-5022-00 and GPO-A-OO-05-00022-00), the Contraceptive and Reproductive Health Technologies Research and Utilization Program, and the University of North Carolina at Chapel Hill Center for AIDS Research (a National Institutes of Health-funded program; P30 AI50410). The views expressed in this document, however, do not necessarily reflect those of USAID.

PII: S0015-0282(07)02999-8

doi: 10.1016/j.fertnstert.2007.07.1348

Fertility and Sterility
Volume 90, Issue 4 , Pages 965-971 , October 2008

Article Tools

* Image Usage & Resolution